There is a reason we are so focused on immuno-oncology at IMV. The advent of therapies that include checkpoint inhibitors is giving hope to thousands of patients who, even five years ago, had run out of options. But these therapies have serious limitations—not in potential efficacy, but in the number of patients predisposed to their benefits.
We are part of a global race to expand the breadth and depth of patients who respond to immunotherapy. The hallmark of our immuno-oncology program is to advance T cell-activating therapies that can activate and direct T cell responses, a mechanism of action (MOA) that can be synergistically combined with other approaches, including immuno-modulators and checkpoint inhibitors. We believe that this approach will help significantly expand the number of patients who can be helped by today’s most promising treatments.
The Society for Immunotherapy of Cancer (SITC) convened a Combination Immunotherapy Task Force that identified a roadmap to help broaden the efficacy response for modern immunotherapies:
Our platform is primed to be a key T cell activating technology. Our lipid-based formulation has a unique “depot” effect, which prolongs the immune system’s interaction with the active ingredients and results in a stronger, more sustained response. Our candidates are also able to work synergistically, combining with other immunotherapy agents to enable anti-cancer activity among multiple pathways.
While there are tremendous challenges ahead, the unique MOA of our platform is optimally positioned to be key components of this moonshot, with their:
We have internal and collaborative research and development immuno-oncology programs in recurrent ovarian cancer, DLBCL, and HPV cancers. Our lead candidate DPX-Survivac targets the cancer antigen survivin, a therapeutic target associated with many tumor types. Other cancer-related candidates include DPX-E7, and our DPX-NEO Program.